Alzecure Pharma’s ACD-856 is a positive allosteric modulator (PAM) of TRK receptors that is in phase I trials for AD, and has shown good safety, pharmacokinetics and target engagement in the central ...

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

highly selective GABA A-α3 positive allosteric modulator. As its first indication, Acadia plans to study SAN711 for essential tremor, a neurological condition that includes shaking or trembling ...